JMS-17-2 hydrochloride is a potent and selective CX3CR1 antagonist (IC50 = 0.32 nM) that reduces metastasis and colonization of breast cancer cells; it significantly inhibits tumor growth in both skeletal and visceral organs in SCID mice bearing MDA-231 xenografts when administered intraperitoneally at 10 mg/kg twice daily for three weeks.